semaglutide flow study chart. †Participants who initiated oral and Long-term kidney outcomes of semaglutide
Description
First-time prescribing of AOM semaglutide decreased again this quarter (-11.75%), while prescribing of AOM tirzepatide increased (46.37%)
This delayed gastric emptying is central to semaglutide's appetite-suppressing effects but can also contribute to reduced food intake
Thus, the weekly tirzepatide dose was increased to 5 mg at 30 days from tirzepatide therapy initiation
This study was completed by two teams that worked independently, each composed of a clinician and research scientists
[DOI] [PubMed] [Google Scholar] 822.Hamman RF, Wing RR, Edelstein SL, et al
